Navigation Links
Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimer's Disease From Merck
Date:12/21/2011

Previously, Dr. Hefti was Senior Vice President of Neuroscience Research at Merck, Director of Neuroscience Research at Genentech, and a Professor at the University of Southern California and Associate Professor at the University of Miami.

"The recent failures of a gamma secretase inhibitor and the limited efficacy observed so far with non-selective amyloid beta immunotherapies indicates that industry may have been focused on suboptimal targets within the amyloid beta pathways," stated Dr. Hefti. "Our Merck colleagues successfully advanced anti-ADDL antibody therapeutics to a late pre-clinical development stage based on antibodies that we believe will allow Acumen to develop a best in class, disease modifying therapy for Alzheimer's disease."

William Goure, Ph.D., has been appointed Acumen's Chief Operating Officer, a position he formerly held.

About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals is a development stage biotechnology company focused on discovering and developing best in class therapeutics and diagnostics for Alzheimer's disease. Acumen owns or has exclusive license rights to key patents, related intellectual property and drug development capabilities relating to amyloid beta soluble oligomers, now widely believed to be an underlying cause of Alzheimer's disease. Acumen is partnered with Merz Pharmaceuticals, GmbH for the development of certain small molecule therapeutics for Alzheimer's disease.


'/>"/>
SOURCE Acumen Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
2. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
5. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
6. Access Pharmaceuticals Signs Agreement for CobaCyte® and CobOral® in RNAi Therapeutic Delivery
7. Radient Pharmaceuticals Announces Proxy Resolutions Approved at Special Meeting of Stockholders
8. Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
9. Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results
10. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Credit Suisse Healthcare Conference on November 9, 2011
11. Optimer Pharmaceuticals to Present at 20th Annual Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... (PRWEB) January 14, 2014 In recent ... motives and methods in product development and promotion has ... industry. This mistrust, fueled by concerns about the insidious ... by reports of spectacular fines to the world’s biggest ...
(Date:1/14/2014)... 14, 2014 Global Record Systems, ... information technology solutions for patients, physicians, the biopharmaceutical ... announced today the signing of a three-year Research ... Drug Administration (FDA). This initiative is designed ...
(Date:1/14/2014)... Cardiff, UK (PRWEB) January 13, 2014 ... leader with more than 20 years in the industry, ... and photonics . Hainsey will serve as the society’s ... have Dr. Hainsey join SPIE as our Technology Strategist, ...
(Date:1/14/2014)... January 14, 2014 During the 1600’s through ... as “The Doctor’s Plague.” In this time period, doctors did ... led, at times, to the death of vulnerable patients. In ... know that they may be unwittingly transmitting herpes viruses to ...
Breaking Biology Technology:The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... , the leading meeting place for buyers and sellers ... Pharma Sourcing Conference to be held December 6-7, 2011 ... The two day program will be jointly hosted by ... issues that global chemical and pharmaceutical industry players are ...
... 26, 2011 Immune Design Corp. (IDC), a ... immunotherapies for infectious disease, cancer and allergy, announced ... research collaboration with Sanofi-Aventis to investigate the use ... toll–like receptor 4 (TLR-4) agonist, in the field ...
... RICHMOND, Calif., Oct. 25, 2011 Sangamo BioSciences, Inc. (Nasdaq: ... results and accomplishments. For the third quarter ... of $9.6 million, or $0.18 per share, compared to a ... the same period in 2010. As of September 30, 2011, ...
Cached Biology Technology:Informex Introduces a Thorough Global Pharma Perspectives Conference 2Sangamo BioSciences Reports Third Quarter 2011 Financial Results 2Sangamo BioSciences Reports Third Quarter 2011 Financial Results 3Sangamo BioSciences Reports Third Quarter 2011 Financial Results 4Sangamo BioSciences Reports Third Quarter 2011 Financial Results 5Sangamo BioSciences Reports Third Quarter 2011 Financial Results 6
(Date:7/9/2014)... Sexual selection refers to species, selection for traits ... type of natural selection enhances opportunities to mate, the ... Biologists at the University of California, Riverside have now ... of a placenta are linked. Describing the life ... the family Poeciliidae, the researchers found that species with ...
(Date:7/9/2014)... July 9, 2014Biofuels derived from the oils produced by ... fuels. To achieve this goal, optimization of cost effective ... pond systems, is needed. Sapphire Energy has developed an ... pond algae cultivation systems, described in Industrial Biotechnology ... publishers. The article is available on the Industrial ...
(Date:7/9/2014)... Guelph scientist that involved fitting bumblebees with tiny ... neonicotinoid pesticide hampers bees, ability to forage for ... professor in Guelph,s School of Environmental Sciences, and ... July 9 in the British Ecological Society,s journal ... how long-term pesticide exposure affects individual bees, day-to-day ...
Breaking Biology News(10 mins):Biologists link sexual selection and placenta formation 2Biologists link sexual selection and placenta formation 3Biologists link sexual selection and placenta formation 4Controlling contamination in open algae ponds for biofuels 2Bee foraging chronically impaired by pesticide exposure: Study 2
... Assist with Solutions and Services to Support U.S. Army,s ... International Inc (NYSE: CAI ) announced today ... support the U.S. Army,s Biometrics Task Force. CACI received ... and Support Services - Unrestricted (BOSS-U) contract vehicle. The ...
... strategic farming practices might be part of the solution ... on 15 January in Current Biology , a ... reflect sunlight back out to space, summertime temperatures could ... much of central North America and mid-latitude Eurasia. That ...
... Mean Time / 13:00 Eastern Standard Time (TORONTO): Scientists ... have detected evidence that DNA may not be the ... called epigenetics may also account for some inherited traits ... of genetics and inheritance, and potentially provide a new ...
Cached Biology News:CACI Awarded a Prime Position on $500 Million, Multiple-Award Program with Biometrics Operations and Support Services 2CACI Awarded a Prime Position on $500 Million, Multiple-Award Program with Biometrics Operations and Support Services 3CACI Awarded a Prime Position on $500 Million, Multiple-Award Program with Biometrics Operations and Support Services 4Strategic farming practices could help mitigate global warming 2Rethinking the genetic theory of inheritance 2
GOAT ANTI HUMAN PSA (ISOFORM 1)...
Human Carnosine Dipeptidase 1 Affinity Purified PAb...
... and P-selectin glycoprotein ligand-1 (PSGL-1) mediate the ... surface of endothelial cells at sites of ... of PSGL-1 in mediating the interaction between ... completely blocks recognition of PSGL-1 by either ...
Mouse Anti-Human MCAF-(MCP-1)...
Biology Products: